DNA methylation profiling distinguishes histological subtypes of renal cell carcinoma

Renal cell carcinoma (RCC) accounts for around 3% of cancers in the UK, and both incidence and mortality are increasing with the aging population. RCC can be divided into several subtypes: conventional RCC (the most common, comprising 75% of all cases), papillary RCC (15%) and chromophobe RCC (5%). Renal oncocytoma is a benign tumor and accounts for 5% of RCC. Cancer and epigenetics are closely associated, with DNA hypermethylation being widely accepted as a feature of many cancers. In this study the DNA methylation profiles of chromophobe RCC and renal oncocytomas were investigated by utilizing the Infinium HumanMethylation450 BeadChips. Cancer-specific hypermethylation was identified in 9.4% and 5.2% of loci in chromophobe RCC and renal oncocytoma samples, respectively, while the majority of the genome was hypomethylated. Thirty (hypermethylated) and 41 (hypomethylated) genes were identified as differentially methylated between chromophobe RCC and renal oncocytomas (p < 0.05). Pathway analysis identified some of the differentially hypermethylated genes to be involved in Wnt (EN2), MAPK (CACNG7) and TGFβ (AMH) signaling, Hippo pathway (NPHP4), and cell death and apoptosis (SPG20, NKX6-2, PAX3 and BAG2). In addition, we analyzed ccRCC and papillary RCC data available from The Cancer Genome Atlas portal to identify differentially methylated loci in chromophobe RCC and renal oncocytoma in relation to the other histological subtypes, providing insight into the pathology of RCC subtypes and classification of renal tumors.

[1]  C. Ricketts,et al.  Genome-wide CpG island methylation analysis implicates novel genes in the pathogenesis of renal cell carcinoma , 2012, Epigenetics.

[2]  M. Esteller,et al.  Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome , 2011, Epigenetics.

[3]  R. Müller,et al.  NPHP4, a cilia-associated protein, negatively regulates the Hippo pathway , 2011, The Journal of cell biology.

[4]  R. Lothe,et al.  SPG20, a novel biomarker for early detection of colorectal cancer, encodes a regulator of cytokinesis , 2011, Oncogene.

[5]  N Clarke,et al.  Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma , 2011, Oncogene.

[6]  P. A. Futreal,et al.  Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma , 2010, Nature.

[7]  E. Maher.  Genetics of Familial Renal Cancers , 2010, Nephron Experimental Nephrology.

[8]  E. Maher,et al.  Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics , 2010, Genome Medicine.

[9]  P. Karakiewicz,et al.  Treatment of metastatic renal cell carcinoma , 2010, Nature Reviews Urology.

[10]  Ximing J. Yang,et al.  Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma , 2010, BMC Cancer.

[11]  W. Linehan,et al.  The genetic basis of kidney cancer: a metabolic disease , 2010, Nature Reviews Urology.

[12]  Gurpreet W. Tang,et al.  Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes , 2009, Nature.

[13]  Bin Tean Teh,et al.  MicroRNA profiling of human kidney cancer subtypes. , 2009, International journal of oncology.

[14]  J. Ragoussis,et al.  CpG methylation profiling in VHL related and VHL unrelated renal cell carcinoma , 2009, Molecular Cancer.

[15]  Börje Ljungberg,et al.  High-resolution DNA copy number and gene expression analyses distinguish chromophobe renal cell carcinomas and renal oncocytomas , 2009, BMC Cancer.

[16]  Bin Tean Teh,et al.  Somatic mutations of the histone H3K27 demethylase, UTX, in human cancer , 2009, Nature Genetics.

[17]  A. Feinberg,et al.  Genome-wide methylation analysis of human colon cancer reveals similar hypo- and hypermethylation at conserved tissue-specific CpG island shores , 2008, Nature Genetics.

[18]  Pan Du,et al.  lumi: a pipeline for processing Illumina microarray , 2008, Bioinform..

[19]  B. Teh,et al.  Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma. , 2005, Cancer research.

[20]  Maria Merino,et al.  Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. , 2002, Cancer cell.

[21]  A. Paetau,et al.  Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer , 2002, Nature Genetics.

[22]  H. Moch,et al.  Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. , 2001, Cancer research.

[23]  Chun Xing Li,et al.  Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3 , 2000, Nature Genetics.

[24]  B. Delahunt,et al.  The Heidelberg classification of renal cell tumours , 1997, The Journal of pathology.

[25]  S. Scherer,et al.  Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas , 1997, Nature Genetics.

[26]  J. Gnarra,et al.  Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.